BRAF and melanoma: Recent approval and early phase trials with immune checkpoint inhibitors, such as ipilimumab and nivolumab, BRAF inhibitors (e.g. Dabrafanib) and MEK inhibitors (e.g. Binimetinib) has begun for adolescents with advanced malignant melanoma at selected pediatric centers (35).